Bevacizumab in combination with atezolizumab and chemotherapy led to improvements in progression-free survival and duration of response in patients with advanced biliary tract cancer. The addition of ...

This month, the European Medicines Agency (EMA) gave marketing authorization to bevacizumab-vikg (Lytenava, Outlook Therapeutics) for the treatment of neovascular (wet) age-related macular ...

New York, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Bevacizumab Biosimilars Global Market Report 2023" - https://www ...

Flashback Foreword: Bevacizumab and FOLFOX4 for Colorectal Cancer and Bevacizumab Versus Placebo Plus Oxaliplatin-Based Chemotherapy in Metastatic Colorectal Cancer Patients with MCRC were randomly ...

The FDA has approved bevacizumab-maly (Alymsys) developed by Amneal Pharmaceuticals and mAbxience. This marks the third bevacizumab, referencing Avastin, approved in the United States. The first ...

Median overall survival (OS) was about 14 months with cisplatin-containing chemotherapy when paired with either placebo or the angiogenesis inhibitor bevacizumab (Avastin). Progression-free ...

05, assuming that median OS values were 13 and 16.5 months in the single-agent bevacizumab and pemetrexed plus bevacizumab arms, respectively (HR, 0.787). One-sided tests were performed for OS as a ...

To compare the quality and stability of unlicensed, repackaged bevacizumab intended for intravitreal injection, as provided by five licensed compounding pharmacies in the United Kingdom ...

The Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP) study was a prospective, randomized, stratified, controlled, multicenter trial that compared intravitreal ...

Bevacizumab, a humanized anti–vascular endothelial growth factor monoclonal antibody, has shown single-agent activity in women with recurrent tumors. Thus, we aimed to evaluate the addition of ...